CYAD - Celyad Oncology gives Q4 update and 2023 outlook
- Biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell therapies, Celyad Oncology ( NASDAQ: CYAD ) gives Q4 outlook , expects FY 2022 unaudited treasury position of €12.4M ($13.3M).
- The company is now prioritizing internal discovery endeavors to tackle the major current limitations of CAR T-cell therapies
- Net cash burn during Q4 2022 amounted to €1M, in line with expectations.
- The company projects that its existing cash and cash equivalents should be sufficient to fund operating expenses and capital expenditure requirements into Q4 2023.
For further details see:
Celyad Oncology gives Q4 update and 2023 outlook